Literature DB >> 15871513

Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells.

Christiana Charalambous1, Florence M Hofman, Thomas C Chen.   

Abstract

OBJECT: Glioblastomas multiforme (GBMs) are hypervascular tumors characterized by endothelial cell (EC) proliferation. There is increasing evidence that ECs that infiltrate systemic tumors are different from normal blood vessel cells; whether this difference is seen in the central nervous system between GBM and normal brain tissue is not known. The goal of this investigation was to characterize and compare the functional and phenotypic properties of GBM-associated ECs and normal brain ECs.
METHODS: Human ECs were isolated from fresh tissue specimens, purified using flow cytometry, and characterized by immunostaining. Proliferation was measured by determining bromodeoxyuridine incorporation and Ki-67 staining, and by performing the monotetrazolium assay. The migration rate of the cells was determined using the modified Boyden chamber technique. Apoptosis was evaluated by performing the TUNEL assay, cell death enzyme-linked immunosorbent assay (ELISA), and annexin V staining. Growth factor production was analyzed using the ELISA technique. The brain tumor ECs differed from normal brain ECs morphologically and by their expression and distribution of specific markers (that is, vascular endothelial cadherin [VE-cadherin] and CD31). Functional differences between the two cell populations were also evident. The brain tumor ECs proliferated more slowly and underwent less apoptosis than normal brain ECs; however, the tumor ECs migrated faster than the normal ECs. The normal ECs were sensitive to growth factors such as vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1), whereas the tumor ECs were not. In addition, the brain tumor ECs constitutively produced higher levels of ET-1 and VEGF, compared with the normal ECs.
CONCLUSIONS: The data demonstrated that ECs derived from normal brain and from GBMs have significant phenotypic and functional distinctions. Further characterization of brain tumor ECs is essential for efficient antiangiogenic treatment of gliomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871513     DOI: 10.3171/jns.2005.102.4.0699

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

1.  Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.

Authors:  Mai T Ngo; Brendan A C Harley
Journal:  Biomaterials       Date:  2018-06-13       Impact factor: 12.479

2.  Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Authors:  Sun-Jin Kim; Ho Jeong Lee; Mark Seungwook Kim; Hyun Jin Choi; Junqin He; Qiuyu Wu; Kenneth Aldape; Jeffrey S Weinberg; W K Alfred Yung; Charles A Conrad; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2015-06-23       Impact factor: 12.531

3.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Authors:  Nadja Müller; Susanne Michen; Stefanie Tietze; Katrin Töpfer; Alexander Schulte; Katrin Lamszus; Marc Schmitz; Gabriele Schackert; Ira Pastan; Achim Temme
Journal:  J Immunother       Date:  2015-06       Impact factor: 4.456

4.  Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death.

Authors:  Nancy McLaughlin; Borhane Annabi; Marie-Paule Lachambre; Kwang Sik Kim; Jean-Paul Bahary; Robert Moumdjian; Richard Béliveau
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

Review 5.  Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.

Authors:  Amitesh Verma; Sarwish Rafiq
Journal:  Cancer Treat Res       Date:  2022

6.  Molecular therapeutic targets for glioma angiogenesis.

Authors:  Shingo Takano; Toshiharu Yamashita; Osamu Ohneda
Journal:  J Oncol       Date:  2010-04-18       Impact factor: 4.375

7.  Glioma-associated endothelial cells are chemoresistant to temozolomide.

Authors:  Jenilyn J Virrey; Encouse B Golden; Walavan Sivakumar; Weijun Wang; Ligaya Pen; Axel H Schönthal; Florence M Hofman; Thomas C Chen
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

8.  Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells.

Authors:  Jenilyn J Virrey; Dezheng Dong; Caryn Stiles; John B Patterson; Ligaya Pen; Min Ni; Axel H Schönthal; Thomas C Chen; Florence M Hofman; Amy S Lee
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

9.  Increased survivin expression confers chemoresistance to tumor-associated endothelial cells.

Authors:  Jenilyn J Virrey; Shengxi Guan; Wei Li; Axel H Schönthal; Thomas C Chen; Florence M Hofman
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

10.  Vascular gene expression patterns are conserved in primary and metastatic brain tumors.

Authors:  Yang Liu; Eleanor B Carson-Walter; Anna Cooper; Bethany N Winans; Mahlon D Johnson; Kevin A Walter
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.